Viracta Announces Scientific Advisory Board Formation
September 25, 2018 08:00 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO, Sept. 25, 2018 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc., a clinical-stage drug development company advancing innovative approaches to treat viral-associated cancers and other...
Viracta acquires Phase 2 epigenetic drug candidate from Chroma Therapeutics
November 30, 2016 08:00 ET
|
Viracta Therapeutics, Inc.
SAN DIEGO and LONDON, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. announced completion of its acquisition of drug development candidate, VRx-3996, from Chroma Therapeutics, Ltd. ...